Magnetic resonance imaging

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024
Magnetic resonance, Antigen presentation, Patient, Chronic obstructive pulmonary disease, IP, MRI, Inflammatory bowel disease, Pharmacokinetics, Rheumatoid arthritis, Asthma, Fatigue, Joint stiffness, IBD, API, HCQ, Cannabidiol, COPD, Quality of life, Plasma, NDA, FDA, Pain, Lupus erythematosus, Inflammation, Biomarker, Epilepsy, Magnetic resonance imaging, Hydroxychloroquine, Pharmaceutical industry

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Retrieved on: 
Monday, January 22, 2024
Biomarker, Research, ACON, Diagnosis, Low back pain, Software as a service, CO, Algorithm, Spine, Division, Neurosurgery, Barrow Neurological Institute, Pain, Opioid, Magnetic resonance imaging, Education, United, Physician

BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.

Key Points: 
  • Dr. Uribe's practice emphasizes a comprehensive approach to treating the spine and applying minimally invasive spine surgery to complex degenerative disease.
  • Low back pain is an extremely debilitating condition that lacks a noninvasive tool helping me identify the location of a patient's pain.
  • Uribe is a renowned neurosurgeon at one of the world’s leading neurological institutes, Barrow,” said Ryan Bond, Chief Strategy Officer of Aclarion.
  • For information about Nociscan use in Phoenix, please contact Aclarion at [email protected] .

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

Retrieved on: 
Wednesday, January 17, 2024
Patient, MRI, ACON, Intelligence, CO, Algorithm, Low back pain, Magnetic resonance imaging, Biomarker, Surgeon, Physician, Medical imaging

BROOMFIELD, CO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (cLBP), announced today the product release of Nociscan 2.6 which includes support for additional leading magnetic resonance imaging (MRI) scanners. With this product release Nociscan can now be performed on MRI machines beyond those manufactured by Siemens.

Key Points: 
  • With this product release Nociscan can now be performed on MRI machines beyond those manufactured by Siemens.
  • “This important technical milestone expands Nociscan access to healthcare providers and patients throughout the world in a very significant way,” stated Brent Ness, CEO of Aclarion.
  • MRI compatibility with Nociscan has been historically limited to machines manufactured by Siemens.
  • Although Siemens is a major player in the MRI market, we will not rest until Nociscan is available on the leading MRI machines of all manufacturers.

GigXR and CAE Healthcare Form Strategic Alliance to Enhance Training Efficiencies with Multimodal Simulation

Retrieved on: 
Wednesday, January 17, 2024
Software, General Health, Networks, Hardware, Data Management, Training, Technology, Hospitals, University, Artificial Intelligence, Health Technology, Education, Health, Synthetic media, Learning, Patient, Chelsea Handler, Dementia, Miami Dade College, Heart, Pathology, SDK, Myocardial infarction, Advanced cardiac life support, National University of Singapore, Partnership, XR, Basic life support, Asthma, Diagnosis, Atrial fibrillation, CAE, AI, P.C, Government, COPD, DICOM, Generative, Investment, 3D, CKD, ANIMA, Magnetic resonance imaging, Burns, National university, Hypertension, University of Queensland, Lung, Ursuline College, Teaching, IgA nephropathy, Catalog, Medical imaging

GigXR, Inc. , a global provider of extended reality (XR) solutions for healthcare training, and CAE Healthcare announced today their partnership to enhance the efficiency and effectiveness of clinical simulation.

Key Points: 
  • GigXR, Inc. , a global provider of extended reality (XR) solutions for healthcare training, and CAE Healthcare announced today their partnership to enhance the efficiency and effectiveness of clinical simulation.
  • As healthcare staffing shortages surge , combining GigXR’s growing catalog of immersive learning applications with CAE Healthcare’s extensive training infrastructure empowers healthcare institutions to drive learning efficacy and bring more capacity for improved care.
  • "Our platform is designed to be further interoperable with partners like CAE Healthcare, including both their digital and analog capabilities.
  • Now, through this partnership between GigXR and CAE Healthcare, more institutions globally can experience complementary, multimodal healthcare simulation with enhanced training efficiency and effectiveness, showcased during IMSH 2024 at booth #200.

Locked-in syndrome is predominant outcome when children survive drowning, larger study confirms

Retrieved on: 
Friday, January 26, 2024
Code, Learning, Patient, Caregiver, University of Texas System, Research, MRI, Neurology, Intubation, MD, Health, SAN, Pediatric Neurology, School, Perception, Survivor, University, Medicine, Public, Radiology, Disability, Dentistry, Drowning, Family, Fox, Locked-in syndrome, Cognition, Child, Coma, Physician, Magnetic resonance imaging, Emotion, Nursing, Parent, Brain, Teaching

SAN ANTONIO, Texas, Jan. 25, 2024 /PRNewswire-PRWeb/ -- It is a far cry from the traditionally thought-of "vegetative state" in which the mind is absent while the body lives on. Indeed, it is the opposite. Children with "locked-in syndrome," unable to move or speak, are awake and fully aware of their surroundings.

Key Points: 
  • Children with "locked-in syndrome," unable to move or speak, are awake and fully aware of their surroundings.
  • Now, in follow-up research published in the journal Pediatric Neurology, the team reports the largest study to date on the subject.
  • The recently published analysis of 154 children confirms that the predominant outcome of non-fatal pediatric drowning is locked-in syndrome.
  • In the research, 60% of children who survived drowning events (93 of 154) were classified as locked in by family caregivers surveyed by UT Health San Antonio.

US MILITARY MEMBERS NOW ELIGIBLE FOR FOCUSED ULTRASOUND TREATMENT REIMBURSEMENT FOR ESSENTIAL TREMOR

Retrieved on: 
Wednesday, January 24, 2024
Woman, MRI, Neuro, Health, Insurance, Military personnel, Head, Quality of life, Tremor, Veteran, Tricare, Magnetic resonance imaging, Essential tremor, Brain, Health insurance

HAIFA, Israel and MIAMI, Jan. 24, 2024 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that effective immediately, 9.5 million US military members and their covered dependents, covered by Tricare are now eligible for coverage reimbursement for focused ultrasound treatment for essential tremor.

Key Points: 
  • Focused ultrasound, pioneered by Insightec , has emerged as a breakthrough incisionless treatment option that provides targeted relief from essential tremor with minimal risks and downtime.
  • Focused ultrasound treatment for essential tremor utilizes magnetic resonance imaging (MRI) guidance to precisely target and ablate a small area of the brain involved in tremor.
  • Tricare, the largest insurance provider for active and retired military personnel, will now cover the costs associated with focused ultrasound treatment for essential tremor for eligible military members and their covered dependents.
  • Military personnel interested in accessing this service can consult their healthcare providers to determine if they are candidates for focused ultrasound treatment for essential tremor.

Thinning of brain region may signal dementia risk 5-10 years before symptoms

Retrieved on: 
Wednesday, January 24, 2024
School, Risk, University of Texas System, Research, MRI, MD, Health, SAN, Frontotemporal dementia, Diet, Clinical trial, Genetics, University, Neurodegenerative disease, Boston University, Framingham Heart Study, Nursing, Pollution, Journal, Disease, Human, Doctor of Philosophy, Therapy, Magnetic resonance imaging, APOE4, Workforce, Exercise, Caregiver, Bangladesh Technical Education Board, Brain, Seshadri, Medical imaging

SAN ANTONIO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- A ribbon of brain tissue called cortical gray matter grows thinner in people who go on to develop dementia, and this appears to be an accurate biomarker of the disease five to 10 years before symptoms appear, researchers from The University of Texas Health Science Center at San Antonio (also called UT Health San Antonio) reported.

Key Points: 
  • Researchers at The University of Texas Health Science Center at San Antonio discover a possible biomarker indicating dementia risk well in advance.
  • The California volunteers included 44% representation of Black and Hispanic participants, whereas the Massachusetts cohort was predominantly non-Hispanic white.
  • While dementias can affect different brain regions, Alzheimer's disease and frontotemporal dementia impact the cortex, and Alzheimer's is the most common type of dementia.
  • "The relationship between thinning and dementia risk behaved the same way in different races and ethnic groups."

Introduction of Breast Imaging Legislation Will Benefit Thousands of Arizonans

Retrieved on: 
Monday, January 22, 2024
Woman, Patient, House, MRI, Google Images, Breast cancer, Disease, Breast MRI, Magnetic resonance imaging, Biopsy, Diagnosis, Medical imaging

PHEONIX, Jan. 22, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization commends Representative David Cook (R-Globe) for working with Komen to eliminate financial barriers to earlier breast cancer detection by ensuring that everyone has equitable access to diagnostic and supplemental breast imaging.

Key Points: 
  • House Bill 2411 , introduced by Rep. Cook, eliminates the patient out-of-pocket costs for medically necessary diagnostic and supplemental breast imaging including MRIs, ultrasounds, and diagnostic mammograms.
  • It is critical that Arizona eliminates financial barriers that limit access to critical diagnostic and supplemental breast imaging service," said Rep. Cook.
  • An estimated 12% of individuals are called back for additional imaging after an abnormal screening mammogram and require diagnostic imaging.
  • This diagnostic or supplemental imaging is often crucial for individuals previously diagnosed with breast cancer or those considered high-risk.

United States Contrast Media Market Size, Share & Trends Analysis Report 2023: Chronic Diseases and Comorbidities Increase Demand for Imaging Tests - Forecast to 2030

Retrieved on: 
Monday, January 22, 2024
Diabetes, Conditional sentence, Death, MRI, Hospital, Cancer, Agent handling, CT scan, COVID-19, USD, FDA, Chronic condition, Health, Vaccine, Diagnosis, Magnetic resonance imaging, Prevalence, Medical imaging

Contrast Media Market Size, Share & Trends Analysis Report by Modality (Modality, Ultrasound, Magnetic Resonance Imaging (MRI), X-ray/Computed Tomography (CT Scan)), Type, Application, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Contrast Media Market Size, Share & Trends Analysis Report by Modality (Modality, Ultrasound, Magnetic Resonance Imaging (MRI), X-ray/Computed Tomography (CT Scan)), Type, Application, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. contrast media market size is expected to reach USD 3.36 billion by 2030, registering a CAGR of 4.1% from 2023 to 2030
    The increasing burden of chronic diseases is creating a demand for diagnostic imaging procedures, which, in turn, is driving the market growth.
  • Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market.
  • Hence, the increasing prevalence of complex comorbidities and long-term diseases is one of the major drivers of imaging tests and contrast agents; thus, contributing to the market growth.

HealthEdge Partners with Radsource, Excited to Enter Growing Teleradiology Market

Retrieved on: 
Thursday, January 18, 2024
Entrepreneurship, X-ray, MRI, LP, LLP, Partnership, Holland & Knight, Radiology, Magnetic resonance imaging, Physician, Growth, Medical imaging

TAMPA, Fla., Jan. 18, 2024 /PRNewswire/ -- HealthEdge Investment Partners, LLC ("HealthEdge"), a leading lower middle market healthcare-focused private equity fund, announced today that it has completed an investment in Radsource, LLC ("Radsource").

Key Points: 
  • TAMPA, Fla., Jan. 18, 2024 /PRNewswire/ -- HealthEdge Investment Partners, LLC ("HealthEdge"), a leading lower middle market healthcare-focused private equity fund, announced today that it has completed an investment in Radsource, LLC ("Radsource").
  • We are excited to partner with HealthEdge to continue to expand the reach of our industry-leading solutions."
  • HealthEdge Partner Matt Dawson commented, "We are excited to partner with the founders of Radsource and the exceptional team of physicians and non-clinicians they have assembled.
  • Ziegler & Company served as financial advisor, and Holland & Knight LLP served as legal counsel to Radsource.